| (Values in U.S. Thousands) | Mar, 2026 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 |
| Sales | 11,244,000 | 12,205,000 | 13,170,000 | 10,735,000 | 10,606,000 |
| Sales Growth | -7.87% | -7.33% | +22.68% | +1.22% | +38.99% |
| Net Income | 1,614,000 | -801,000 | 2,802,000 | 3,940,000 | 1,872,000 |
| Net Income Growth | +301.50% | -128.59% | -28.88% | +110.47% | +275.15% |
Sanofi (SAN.FP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Fiscal Year End Date: 12/31